drugset / Trial / NCT06360874
A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults
Phase 1
Unknown
104 enrolled
Shenzhen NewDEL Biotech, Co., Ltd
Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate Safety, Tolerability and Pharmacokinetic of ND-003 tablets in Healthy Adults
Timeline
- Start
- 2024-05-09
- Primary completion
- 2024-12
- Completion
- 2025-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ND-003 | Small molecule | 40 mg | Oral |
| Subject | ND-003 | Small molecule | 80 mg | Oral |
| Subject | ND-003 | Small molecule | 160 mg | Oral |
| Subject | ND-003 | Small molecule | 240 mg | Oral |
| Subject | ND-003 | Small molecule | 300 mg | Oral |
Indications
No indication recorded.